Quick Answer
Indivior Pharmaceuticals, Inc. reported Net Income of $210.00 million for fiscal year 2025.
Indivior Pharmaceuticals, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | $210.00M | +2900.0% |
| 2024 | $7.00M | +105.6% |
| 2023 | -$126.00M | -186.4% |
| 2022 | -$44.00M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $42.00M | +90.9% | +133.3% |
| June 30, 2025 | $18.00M | +118.6% | -61.7% |
| March 31, 2025 | $47.00M | -23.0% | +123.8% |
| December 31, 2024 | $21.00M | — | -4.5% |
| September 30, 2024 | $22.00M | — | +122.7% |
| June 30, 2024 | -$97.00M | — | -259.0% |
| March 31, 2024 | $61.00M | — | — |
- Indivior Pharmaceuticals, Inc. showed an increase of +2900.0% in Net Income compared to the prior fiscal year.
- Over the 2022–2025 period, Indivior Pharmaceuticals, Inc.’s net income has grown by 577.3% (from -$44.00 million to $210.00 million).
- The most recent figure is from Indivior Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: